Forgot Password?
Return to Course Listing

CME: The United States CTEPH Proceedings 2021, Part 1


Activity Description / Statement of Need:

***Please note that, in order to access these course materials, you must create a user profile if you do not already have one. Your profile one ScientiaCME's website is unrelated to your profile on North American Thrombosis Forum's (NATF's) website.***


The content of this online activity was originally presented as part of a live event. It is divided into three videos. Learners must view all videos in their entirety and complete a post-activity assessment and evaluation before they are eligible for continuing credit.

The North American Thrombosis Forum's (NATF’s) "United States CTEPH Proceedings 2021" provides a multidisciplinary framework for the evaluation and management of patients with chronic thromboembolic pulmonary hypertension (CTEPH). The activity is comprised of didactic presentations, debates, and panel discussions involving national and international experts in the field.

Covered topics in the series will include:

  • The epidemiology of chronic thromboembolic disease in the US
  • Contemporary approaches to diagnosing CTEPH
  • The latest in surgical advancements
  • The role of pulmonary hypertension (PH) targeted medical therapy and balloon pulmonary angioplasty (BPA) in the management of inoperable CTEPH

Target Audience:

This activity has been designed to provide internists, pulmonologists, cardiologists, cardiovascular surgeons, interventional cardiologists and radiologists, anesthesiologists, thoracic radiologists, nurses, and allied healthcare professionals with state-of-the-art information to evaluate and manage patients with CTEPH.

Supported by educational grants from: Abbott Laboratories; Acceleron Pharma Inc.; Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson; and Boston Scientific Corporation.

This internet enduring material activity is part of a series of activities. Participation in this activity is free of charge.

Release Date: December 15, 2021 -- Expiration Date: December 14, 2022

Faculty: Multiple Faculty,


Understanding CTEPH

Transition from Acute PE to CTEPH: Implications for Future Therapeutics? Sudarshan Rajagopal, MD, PhD, Associate Professor of Medicine, Co-Director, Pulmonary Vascular Disease Center, Duke University Medical Center

Screening for Chronic Thromboembolic Disease and CTEPH - F.A. Klok, MD, PhD (30 minutes)

The Ongoing Challenges of Diagnosing CTEPH -Gustavo Heresi, MD, MS (30 minutes)


The Tools of Diagnosis

Advances in CT and MR Imaging: Implications for CTEPH Diagnosis and Management - Deepa Gopalan, FRCP, FRCR (40 minutes)

The Art of Pulmonary Angiography - Lori Daniels, MD, FACC (30 minutes)

Exercise Testing in Chronic PE - Paul Forfia, MD (30 minutes)


Case Presentations
  1. Symptomatic 6 Months Following a PE…What to Do? Peter Hountras, MD
  2. Is That Acute or Chronic Clot On CT? Sonja Bartolome, MD
  3. VQ, CT, Pulmonary Angiogram…Is It All Necessary? Victor M. Moles, MD

Learning Objectives

By the end of the session the participant will be able to:

  • Discuss an updated understanding of the pathophysiology of CTEPH and apply that information to a patient case
  • Describe the latest diagnostic and evaluative approaches to patients with suspected chronic thromboembolic disease and apply that information to a patient case
  • Discuss advances in pulmonary thromboendarterectomy for patients with chronic thromboembolic disease and CTEPH


ACCME Activity #201861288


Faculty Disclosure and Resolution of COI

Disclosure Relevant Financial Relationships for Faculty, Moderators, Course Planners, and Content Reviewers:

  • William R. Auger, MD, FCPP: Consultant – Bayer, Janssen PH, Cereno Scientific
  • Sonja Bartolome, MD: Consultant – Janssen
  • Todd Bull, MD: Consultant – Bayer; Researcher – Johnson & Johnson, United Therapeutics, Actelion
  • Michael Cuttica, MD: Consultant, Speaker Bureau, Advisory Board, PI – Bayer; Speaker Bureau, Advisory Board, Consultant – United Therapeutics, Janssen
  • Paul Forfia, MD: Consultant – Bayer, Janssen, United Therapeutics
  • Deepa Gopalan, FRCP, FRCR: Speaker – Bayer Pharma AG
  • Gustavo Heresi, MD: Consultant, non-branded Speakers Bureau – Bayer; Consultant – Janssen
  • Peter Hountras, MD: Primary Investigator, Phase 3 Trial – Actelion
  • Kim M. Kerr, MD: Research Support – Bayer; Consultant – Actelion
  • F.A. Klok, MD, PhD: Unrestricted Research Support – Bayer, Actelion, BSCI
  • Sudarshan Rajagopal, MD, PhD: Research: United Therapeutics, Janssen, Corvista; Paid consulting – Janssen, United Therapeutics, Bayer, Altavant, Insmed, Apie Therapeutics; Patent – Licensed to Polarean
  • Alison Witkin, MD: Advisory Board, United Therapeutics


Individuals with no conflicts of interest to disclose:

  • Lori Daniels, MD, FACC
  • Victor M. Moles, MD
  • Charles Turck, PharmD, BCPS, BCCCP, President, ScientiaCME (Reviewer)


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.